For those patients resistant or intolerant to BCR-ABL inhibitor imatinib, second- and third-generation tyrosine kinase inhibitors are successfully used in distinct CML disease states [98,99,100,101]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.